 Home > Active Ingredient News > Study of Nervous System > NEJM: Eli Lilly’s Phase II Aβ Antibody Clinical Results Announced: The primary endpoint was reached, the secondary endpoint was missed

NEJM: Eli Lilly’s Phase II Aβ Antibody Clinical Results Announced: The primary endpoint was reached, the secondary endpoint was missed

 Last Update: 2021-03-21
 Source: Internet
 Author: User

Tags

early allergen introduction

state slim phase 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On March 13, 2021, the Phase II clinical results of Eli Lilly’s Aβ antibody Donanemab were published in the New England Journal (clinical number: NCT03367403).

Phase II clinical results of Donanemab Phase II clinical results of Donanemab New England Journal

Eli Lilly conducted a Phase II trial of Donanemab in patients with early symptomatic Alzheimer's disease who had tau and amyloid deposits on positron emission tomography (PET).

The main result was the change from baseline in scores on the Alzheimer's Disease Comprehensive Rating Scale (iADRS; range, 0 to 144, lower scores indicate greater cognitive and functional impairment) at 76 weeks.

In the study, a total of 257 patients were enrolled; 131 were assigned to receive Donanemab treatment, and 126 received placebo.

The change in iADRS score from baseline was: Donanemab was -6.

However, there is no substantial difference in the statistics of most secondary results.

Therefore, in patients with early Alzheimer's disease, the comprehensive score of cognition and activities of daily living in the Donanemab treatment group at 76 weeks was better than that of the placebo group, but the secondary results were uneven.

It will take longer and larger-scale trials.

Original source:

Mark A.

Mark A.
Mintun et al.
Donanemab in Early Alzheimer's Disease .
NEJM (2 Donanemab in Early Alzheimer's Disease 021) leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Sodium bromide airuike

CAS No.: 7647-15-6

Industrial Grade

$10/KG EXW

Brivaracetam357336-20-0

CAS No.: 357336-20-0

API Grade

$100/KG EXW

Quetiapine fumarate CAS 111974-72-2

CAS No.: 111974-72-2

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.